MS and Demyelinating Disorders

TG Therapeutics has indicated it plans to submit a supplemental BLA to the FDA in the second half of 2026, seeking approval for the consolidated initiation regimen of ublituximab-xiiy.

Catch up on any of the neurology headlines you may have missed in June 2026, compiled into 1 place by the NeurologyLive® team.

A 10-protein serum signature identified through longitudinal proteomics significantly stratified relapse risk in NMOSD patients, with the 2 strongest markers showing an association with relapse more than 8 months out on average.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 3, 2026.

The 510(k) clearance was supported by a 3-study, 159-patient registrational program showing a 45.5% increase in response rate vs physical therapy alone, and includes Medicare coverage at launch.

Tom Fuchs, MD, PhD, postdoctoral researcher at the MS Center at Amsterdam University Medical Center, shared his reaction to the European Commission's approval of tolebrutinib for nonrelapsing secondary progressive MS.

New findings suggest that monoclonal antibody therapy was associated with a 34% lower risk of relapse in patients with AQP4-IgG seropositive NMOSD compared with those who were seronegative.

Jens Kuhle, MD, PhD, head of the Multiple Sclerosis Centre at University Hospital Basel, discusses the EU approval of tolebrutinib for nonrelapsing SPMS and its implications for treating disability progression.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 26, 2026.

The European Commission has approved Cenrifki (tolebrutinib) for nrSPMS without relapses in the last two years, a milestone that arrives despite the drug's failed US submission and a regulatory pathway that has been anything but linear.

FDA’s clearance for PTD802, a first-in-class GPR17 antagonist designed to promote remyelination, enables initiation of a first-in-human phase 1 study in healthy volunteers and advances a novel regenerative approach for multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 19, 2026.

Here's some of what is coming soon to NeurologyLive® this week.

Neurologists Sarah Simmons, MD, PhD, and Fatma Inanici, MD, PhD, discuss how the combination of noninvasive cervical spinal cord stimulation with exercise therapy can improve upper extremity function in people with MS.

Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.

Daniel Vitt, PhD, chief executive officer of Immunic, discussed the dual mechanism of vidofludimus calcium, ongoing phase 3 ENSURE trials in relapsing MS, and phase 2 CALLIPER findings suggesting potential neuroprotective effects in progressive MS.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 5, 2026.

Mitzi Joi Williams, MD, sits down with sleep specialist Shantel Branson, MD, to discuss how sleep impacts brain health, memory, mood, and long-term neurologic well-being.

At CMSC 2026, the neuroimmunologist and director at OhioHealth MS Center, discussed results from the phase 3 FENhance 1 and 2 studies, highlighting significant reductions in relapse rates and robust MRI outcomes. [WATCH TIME: 3 minutes]

As the MS community reflects on World MS Day, Alla Wilson, a clinical ambulatory pharmacist at Shields Health Solutions, discusses how integrated specialty pharmacy models can improve treatment access, adherence, and patient-reported outcomes for multiple sclerosis.

The neurologist at Orlando Health discussed findings from an analysis of cladribine tablets in patients aged 50 years and older with relapsing multiple sclerosis presented at CMSC 2026. [WATCH TIME: 7 minutes]